Clinical and Developmental ImmunologyVolume 2012 (2012), Article ID 980250, 15 pagesdoi:10.1155/2012/980250

Review Article

scFv Antibody: Principles and Clinical Application

Zuhaida Asra Ahmad,¹ Swee Keong Yeap,² Abdul Manaf Ali,³ Wan Yong Ho,¹ Noorjahan Banu Mohamed Alitheen,¹ and Muhajir Hamid1,4

¹Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Selangor, 43400 Serdang, Malaysia²Institute of Bioscience, Universiti Putra Malaysia, Selangor, 43400 Serdang, Malaysia³Faculty of Agriculture and Biotechnology, Universiti Sultan Zainal Abidin, Kampus Kota, Jalan Sultan Mahmud, 20400 Kuala Terengganu, Malaysia⁴Department of Bioprocess Technology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Selangor, 43400 Serdang, Malaysia

Received 10 November 2011; Accepted 7 January 2012

Academic Editor: T. Nakayama

Copyright © 2012 Zuhaida Asra Ahmad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

To date, generation of single-chain fragment variable (scFv) has become an established technique used to produce a completely functional antigen-binding fragment in bacterial systems. The advances in antibody engineering have now facilitated a more efficient and generally applicable method to produce Fv fragments. Basically, scFv antibodies produced from phage display can be genetically fused to the marker proteins, such as fluorescent proteins or alkaline phosphatase. These bifunctional proteins having both antigen-binding capacity and marker activity can be obtained from transformed bacteria and used for one-step immunodetection of biological agents. Alternatively, antibody fragments could also be applied in the construction of immunotoxins, therapeutic gene delivery, and anticancer intrabodies for therapeutic purposes. This paper provides an overview of the current studies on the principle, generation, and application of scFv. The potential of scFv in breast cancer research is also discussed in this paper.

1. Introduction

Antibodies are a modular defense system that identify and neutralize foreign objects like bacteria and viruses. Each of them could recognize a specific antigen unique to its target as they possess the antigen-binding sites, a paratope (a structure analogous to a lock) located at the upper tips of the “Y” shaped antibody molecules. This paratope is specific for one particular epitope (analogous to a key), displayed on the particular antigen, allowing these two structures to specifically bind together. Thus, this mechanism could allow an antibody to tag a microbe as well as an infected cell to be attacked by other parts of the immune system and also to directly neutralize its target [1].

2. Recombinant Antibody Technology

Being a major part of the immune system, antibodies represent a powerful weapon system in defending our body against non-self-agents. But, to interact with as many foreign structures as possible, an enormous number of different molecules, bearing different specificities, are needed. This diversity can be produced through somatic recombinant and hypermutagenesis of a set of variant genes [2].

During the past decade, advances in recombinant antibody technology have greatly facilitated the genetic manipulation of antibody fragments [4, 5]. The genetic manipulation of recombinant antibodies thus improved our understanding about the structure and functional organization of immunoglobulins. Further, these advances have led the development of a large variety of engineered antibody molecules for research, diagnosis, and therapy with specificities out of reach of conventional antibody technology. Once cloned, it is then possible to increase the affinity and specificity of antigen binding by mimicking somatic hypermutation during an immune response [6]. It may even be possible to replace the existing practices of animal immunization and hybridoma development through a bacterial system capable of synthesizing and expressing practically unlimited quantities of antibodies to almost any antigen.

Since 1975, Kohler and Milstein have introduced the hybridoma technology which enabled a defined specificity of monoclonal antibodies to be produced in consistent quality as well as in large quantities in the laboratory. Since then, monoclonal antibodies (mAbs) have been favored as they can be produced in unlimited quantities to practically bind to any antigen and are more easily standardized [7, 8]. Besides monoclonal antibodies, hybridoma cells that are successfully produced could then serve as a starting material in the generation of Fab, or Fv fragments in lymphoid or nonlymphoid cells [9]. Monoclonal antibodies face several difficulties, as they are almost exclusively murine in origin thus could create human anti-mouse antibody (HAMA) when introduced to human therefore limits their clinical applications [7, 8]. Added to this, monoclonal antibody producing technology is very laborious and time consuming. Furthermore, small mammals like mice do not always provide the high-affinity antibody response to particular antigen needed for sensitive assay development [10]. These limitations of traditional techniques have led several research groups to investigate the use of phage display in producing scFv antibodies.

The first study in producing recombinant antibodies in bacteria was hampered due to improper folding and aggregation of the polypeptide in the bacterial cytoplasm [4, 11]. In order to overcome these problems, Skerra and Plückthun [12] have introduced a one-step-forward technology whereby only parts of the antibody molecule (Fab or Fv fragments) are used for expression purposes. The breakthrough for competent E. coli expression of antibody fragments yet was brought by introducing several types of vectors (e.g., phagemid) to be used in the recombinant antibody construction. These vectors could offer soluble antibody secretion directly into the periplasm space by means of its oxidizing environment that contributes for the correct formation of disulphide bonds between the antibody domains [12, 13].

Recently, the technology has been improved through recombinant DNA technology and antibody engineering whereby antibody genes can now be cloned and expressed successfully as a fragment in bacteria [12], on mammalian cell and yeast [15], plant [16], and also insect cells [17]. One advantage of this new technology is that they could retain the intact antigen binding site (paratope) while reducing the size of the antibody molecule. In comparison to the parental antibody, these minimized antibodies have several advantages in clinical practices including better tumor penetration, more rapid blood clearance, and lower retention times in nontarget tissue and also to reduced immunogenicity. It also could lead to the expression of the functional antibody and their fusion in bacteria and also allow their display on a filamentous phage. In addition, the combination of small antibody molecule together with the efficient microbial production systems can finally lead to the production of a homogenous protein in sufficient amounts for diagnostic and therapeutic purposes as well as in structural studies [18–20].

Thus, with the latest technology, a wide variety of genetically engineered antibodies have been produced as reviewed by a number of researchers [21–23] including Fab fragments [24], Fv fragments in which the domains are held together by noncovalent forces [12] and so-called single-chain fragment variable or scFv (single chain fragment variable) antibodies in which the genes of and dare joined together with a short flexible peptide linker or with disulfide bond [25]. Alternatively, the minimized antibodies molecule could also serve as a building block for the construction of new recombinant proteins for different purposes. For instance, antibody with the same affinity have been successfully fused to construct bivalent antibodies [26] or multivalent antibodies [27, 28] and two antibody fragments with different specificities have been fused to construct bispecific antibodies [29].

3. Single-Chain Fragment Variable (scFv)

Fv fragment is the smallest unit of immunoglobulin molecule with function in antigen-binding activities. An antibody in scFv (single chain fragment variable) (Figure 1) format consists of variable regions of heavy () and light () chains, which are joined together by a flexible peptide linker that can be easily expressed in functional form in E. coli, allowing protein engineering to improve the properties of scFv (single chain fragment variable) such as increase of affinity and alteration of specificity [30].

Figure 1: Antibody model showing subunit composition and domain distribution along the polypeptide chains. Single-chain fragment variable (scFv) antibody generated by recombinant antibody technology appears in the shaded area.

The length of the flexible DNA linker used to link both of the domains is critical in yielding the correct folding of the polypeptide chain. Previously, it has been estimated that the peptide linker must span 3.5 nm (35 Å) between the carboxy terminus of the variable domain and the amino terminus of the other domain without affecting the ability of the domains to fold and form an intact antigen-binding site [31]. In addition to the linker peptides designed de novo, peptide sequences derived from known protein structure have been applied to provide a compatible length and conformational in bridging the variable domains of a scFv (single-chain fragment variable) without serious steric interference [32–34]. Apart from the length of the linker, their amino acid composition also plays an important role in the design of a viable linker peptide. They must have a hydrophilic sequence in order to avoid intercalation of the peptide within or between the variable domains throughout the protein folding [35]. Nowadays, the most extensively used designs have sequences comprising stretches of Gly and Ser residues which meant for flexibility and or together with the charged residues such as Glu and Lys interspersed to enhance the solubility [36].

4. The Generation of scFv (Single-Chain Fragment Variable) Antibodies

scFv (single chain fragment variable) antibodies have been constructed mainly from hybridoma [16, 37–39], spleen cells from immunized mice [40–42], and B lymphocytes from human [43–45]. scFv (single chain fragment variable) is a noncovalent heterodimer comprised of the and domains [12] in which can then be used in the construction of recombinant scFv (single chain fragment variable) antibody. In order to attain them, mRNA is first isolated from hybridoma (or also from the spleen, lymph cells, and bone morrow) followed by reverse transcribed into cDNA to serve as a template for antibody genes amplification (PCR). With this method, large libraries with a diverse range of antibody and genes could be created [43]. One successful approach to recombinant antibody production has been developed by McCafferty and coworkers in which they utilized the phage recombinants that are displaying antibody at their tips together with the new techniques of affinity selection, called biopanning step. The work by McCafferty et al. [14] thus has opened the opportunity for in vitro selection of scFv (single chain fragment variable) from large libraries of variable domains circumventing the traditional hybridoma method.

In the scFv (single-chain fragment variable) construction, the order of the domains can be either -linker- or -linker- and both orientations have been applied [46–48]. Even though Luo et al. [49] have shown that the expression of scFv (single-chain fragment variable) of Pichia pastoris system is -linker- orientation-dependent; most of the scFv (single-chain fragment variable) are constructed in a -linker- orientation. One of the most popular methods used is through PCR assembly [40, 43, 50] which was first described by Horton et al. [51]. In this method, it allows the domains of antibody to be cloned without any prior information about the nucleic acid as well as amino acid sequence of the particular antibody [52]. Moreover, the domains of antibody can be combined by in vitro recombination directly after the PCR of and genes into plasmid [38, 53] or phagemid [54]. Alternatively, scFv (single-chain fragment variable) can also be constructed with sequential cloning [55, 56] or combinatorial infection [57].

Numerous scFv (single-chain fragment variable) have been constructed against hapten [55], protein [46, 58], carbohydrate [59, 60], receptor [16], tumor antigen [44, 61], and viruses [47]. All these scFv (single chain fragment variable) have good potential for use in many fields such as medical therapies and diagnostic applications.

5. The Expression of Antibody Fragments (scFv)

To date, antibody fragments (scFv) have been successfully isolated and displayed as fragments in various expression systems such as mammalian cell and yeast [15], plant [16], and also insect cells [17]. scFv (single-chain fragment variable) antibody can be expressed as correctly folded and directly active proteins or as aggregates requiring in vitro refolding to become active. Depending on the expression system, it varies in their ability to fold and secrete the scFv (single-chain fragment variable) proteins. There are some general regulations to consider on the design of vectors and expression system used with the different hosts and each of this host has advantages and disadvantages for the production of active scFv (single-chain fragment variable) antibody [62]. Nevertheless, the bacterial expression system is most often applied for the production of scFv (single-chain fragment variable) antibody fragments compared to the various expression strategies available.

Recent progress in the perceptive of both genetics and biochemistry of E. coli makes this organism a precious tool as an expression host [63]. Moreover, scFv (single-chain fragment variable) antibody with good folding properties can be expressed economically by using this organism compared to whole antibodies with complicated folding and glycosylation which require slow and expensive cell culture techniques. Apart from that, it also could promise high throughput of recombinant proteins and can be used in multi-plexed cloning, expression, and purification of proteins for structural genomics [64]. Further, this production system is well-studied physiology, genetics, and availability of advanced genetic tools [63, 65, 66], rapid growth, a very high yields up to 10–30% of total cellular protein, a simple way to conduct within a standard molecular biology laboratory, low cost, and the capability to multiplex both expression screening [67] together with the protein production [68].

There are a number of different strategies used to express the recombinant antibody fragments in E. coli as reviewed by investigators [12, 69]. One way is to express scFv (single-chain fragment variable) antibody directly in the cytoplasm of E. coli without using a signal peptide [32, 70]. As a result, the polypeptides are greatly expressed in the reducing environment of bacterial cytoplasm followed by the formation of insoluble aggregates called inclusion bodies. For that reason, the inclusion bodies must be renatured in vitro to improve the correct folding of functional protein by means of appropriate rearrangement of the disulphide bonds [71]. To overcome this problem, a signal peptide is used to direct secretion of the scFv (single-chain fragment variable) antibody into the periplasmic space that lies between inner and outer membranes of gram-negative bacteria [12, 13]. According to the Baneyx [63], this periplasmic space is identified to contain protein such as chaperones and disulphide isomerases, which assist the proper folding of recombinant proteins. Generally, the Fab fragment produced in E. coli is based on the expression of a discistronic operon unit where both of the genes (L and Fd) are controlled by the same promoter and thus allowing synthesis of both chains in an equal amount. During translocation via the inner membrane into the oxidizing environment of the periplasm, the signal peptides attached at the N-terminus are sliced off permitting the chains to fold and assemble and thus lead to the formation of both of the intra- and interdomain sulphide. Until now, periplasmic expression has been extensively employed in the production of various specific scFv (single-chain fragment variable) antibodies. But, in some cases, antibodies are observed as insoluble material since their efficiency and folding are depending on the individual protein [34].

At present, studies on the factor to improve both phage display as well as periplasmic folding of scFv (single-chain fragment variable) fragments have led to the discovery of accessory proteins for decrease aggregation and together with facilitated folding of the scFv (single-chain fragment variable) antibody fragments [72–75]. An antibody in scFv (single-chain fragment variable) format possesses the hydrophobic patches that are buried in a hydrophobic variable or constant interface. Once they are exposed to the solvent, it possibly will promote aggregation during protein folding. By replacement of the hydrophobic residues by hydrophilic ones has been shown to improve the in vivo folding properties of the protein [76].

Alternatively, disulphide bonds of antibodies are also contributing significantly in the stability of the structure and yet make them conserved in evolution. For instance, there are studies that demonstrated that the replacement of the disulphide forming cysteines with other amino acids enabled to produce the same active and correctly folded antibody fragments [77].

6. Phage Display

Beginning in 1985, Smith [78] was first to reveal that foreign DNA fragments can be fused to the gene encoded for pIII coat protein of a nonlytic filamentous phage and expressed as a fusion protein on the virion surface without disturbing the infectivity of the phage. A few years later, McCafferty et al. [14] in their study have successfully demonstrated that a scFv (single-chain fragment variable) fragment can be displayed on the phage surfaces as a functional protein which retains an active antigen-binding domain capability. Therefore, this technology could allow rare clones to be screened and isolated from a large population of phage using any desirable antigen [79]. Since these first applications, the technology has now been widely used to other antibody molecules including Fab fragments [80], disulphide-stabilized Fv fragments [48], and diabodies [81].

There are several types of libraries: phage display libraries (immune, naïve, and synthetic) and ribosomal display libraries. But, each type of library has its limitations and is suitable for different purposes depending on the nature of antigen panned during selection procedure together with the affinity and number of antibodies expected. Based on the source of antibody genes, scFv (single-chain fragment variable), libraries can be divided into three different categories; immune, naïve, and synthetic. Firstly, immune libraries which have been constructed from variable domains of antibody genes of B cells derived from different kinds of immunized animals like mice [82], camel [83], sheep [84], and also humans [85]. In these libraries, the enriched antibodies are biased towards antigen that is used for immunization. Due to the in vivo affinity maturation (by the hosts’ immune system) of the antibodies, this approach always results in a great range of higher affinities of isolated binders as well as the number of binders specific towards the antigen but yet, the construction of the new library for each antigen is needed.

Secondly, naïve libraries, derived from nonimmunized donors of B cells that have been constructed from a pool of -genes of IgM mRNA [86, 87]. Unlike immune libraries, these libraries are not biased towards any antigen and they are utilized in the selection of antibodies against different specificity without the need to construct a new library for each antigen. Therefore, they are particularly useful for the production of antibody fragments which are difficult to generate using hybridoma technology especially against nonimmunogenic or toxic antigens. While the affinities of mAbs produced very much depending on the library size (between 10⁹-10¹⁰ members), even affinities below 1 nM were reported [87]. Generally, the affinities of scFv (single-chain fragment variable) isolated from small naive libraries are lower compared to those isolated from larger libraries [86–89]. For that reason, the size of the library is important for the selection of high-affinity fragments as well as to determine the success rate of selection of phage against a large repertoire of different antigens [86, 87].

Thirdly, the synthetic libraries which also derive from nonimmune sources as their ranges were prepared synthetically by combining germ line gene sequences together with randomized complementary determining regions (CDRs) that are responsible for antigen binding [89, 90]. The majority of synthetic human antibody libraries produced focused on randomizing the CDR3 regions, which are usually most diverse and essentially responsible for antigen binding. Therefore, these libraries are extensively chosen to yield high affinity of monoclonal antibodies. There are a number of large semisynthetic libraries available now; one of the largest called the Griffin-1 library contain human scFv (single-chain fragment variable) fragments (H Griffin, MRC, Cambridge, UK, unpublished data). This study was performed by Griffiths et al. [89] by means of recloning synthetic heavy and light chain variable regions from a 2-lox Fd phage library vector into the pHEN2 phagemid vector. There are also different studies that have been developed to construct fully synthetic scFv (single-chain fragment variable) libraries based on single or multiple variable domains used as scaffold and CDRs of varying composition and length [90, 91].

Other than phage display, there are also libraries constructed using ribosomal display technology which utilized in vitro method to isolate scFv (single-chain fragment variable) directly without involving phage and bacteria organisms. Firstly, the DNA library of scFv (single-chain fragment variable) is transcribed and translated in vitro to create the complex of linked mRNA-ribosome-scFv (single-chain fragment variable) protein which is used for selection on immobilized antigen. The mRNAs that are specifically bound to the antigen then eluted, followed by reverse transcribtion and finally the enriched regenerated DNA pool then employed for the next round of selection [92, 93]. Since it was a relatively new technology, and thus not fully utilized, yet it has the potential to further simplify and shorten during scFv (single-chain fragment variable) selection. These techniques, however, could provide a great tool for the generation of an unlimited number of monoclonal antibodies by means of in vitro as well as in vivo procedure which are biased towards antigen that is interested.

In order to express the antibody fragments on the surface of the filamentous bacteriophage, the immunoglobulin genes can be fused either to the VIII gene [94] or the pIII gene (Figure 2) [14]. The single-stranded DNA genome of the filamentous phage is coated with approximately 2700 copies of the major coat protein (pVIII) and can be fused together with antibody to result in multivalent display of the fragment. While three to five copies of the minor coat protein pIII are located on the tip of the phage, which is responsible for attaching the phage to its bacterial host during infection. As reviewed by researchers [95, 96], the most widely used display format is derived from the use of the phagemid vector and the pIII display, which allows high frequency of monovalent display and therefore is preferred in affinity selection.

Figure 2: Structure of a filamentous phage displaying scFv fragments on its surface [14].

The ultimate aim of phage display is the selection of phage that can bind to the target antigen of interest with high affinity from a huge number of nonspecific phage clones. This is achieved by multiple rounds of phage binding to the antigen, washing to remove the unbound phage followed by elution and retrieval of specifically bound phages. After each round, the eluted phages are amplified by the infection of E. coli for the following selection step. Soluble antibodies are produced in the final round of the bacteria then characterized. There are various types of selection strategy that can be used to attain specific antibodies [95, 96]. Generally, the procedures for selecting against purified antigens rely upon the phage binding affinity for the antigen of desire comparative to phage particles that do not bind, so that it require the antigen to be attached onto a solid support [40, 43, 89]. In the majority of this applications, selection has been carried out by incubating phage on antigen immobilized onto a solid support, such as Immunotubes [90, 97], microtiter plate wells [98], BIAcore sensor chips [97], or columns [98]. Or, the phage library can be incubated using biotinylated antigen in solution, followed by capture of the antigen-phage complex on streptavidin surface [89, 99]. With this approach, antibodies on the basis affinity can be selected by using an antigen concentration much less than the desired dissociation constant Kd [99–101]. In addition, by selecting an appropriate design for the selection procedure, antibodies can too be selected on the basis of kinetic properties [101, 102], improved specificity [103], or phage infectivity [104, 105].

In cases where pure antigen is not available, such as integral membrane protein, or the unknown antigen source (for novel markers on cells or tissues studies), specific antibodies must be isolated using more complex sources, such as whole cells [45, 106, 107] or tissue fragments [55]. In contrast, antibody fragments can also be raised against heterogeneous cell mixtures using fluorescence activated cells (FACs) sorting selection. Firstly, the phage library is incubated with the cells of interest while unbound phage is removed by washing thoroughly. Next, the cells of interest are labeled with a known fluorescence labeled Mab followed by cell sorting step and finally the sorted phages are eluted and amplified [108]. With this technique, unbound phage can be isolated by differential centrifugation of the cell-phage complex throughout an organic phase and the bound phage is recovered in the cell pellet [109].

In most applications, the binding characteristics of antibodies selected from phage libraries are frequently sufficient for further use in research applications, such as ELISA, Western blotting, or immunofluorescence [48]. However, the antibodies affinity or specificity selected from the libraries might be insufficient for diagnostic or therapeutic applications and therefore further improvement is needed. This problem could be improved by targeting mutagenesis to one or more of the CDRs or only a part of them followed by selection of high affinity antibodies [48, 110]. Despite mutagenesis, pairing heavy chain with a library of light chains (chain-shuffling), or vice versa, has been applied to increase the antibodies affinity which is in the nanomolar or picomolar range [42, 111].

In summary, phage display technology has been well developed in which we can generate new specific antibodies by circumventing immunization and consequently could facilitate the generation of antibodies that are difficult or impossible to gain through conventional methods, such as human antibodies and antibodies against self-antigens [86, 95, 112]. Moreover, during the selection procedures, phage display system can too be applied to isolate stable and well-folded proteins, catalyst, or peptide substrates [113].

7. Advantages of Phage-Displayed Single-Chain Variable Fragment (scFv)

There are several advantages of phage-displayed scFv (single-chain fragment variable) over monoclonal antibodies. Firstly, phages are more stable and can be stored up to several years at 4°C [114]. Secondly, they can be produced rapidly and inexpensively just by infecting the E. coli [115]. Thirdly, their genes can be easily manipulated and lastly they can be produced by circumventing hybridomas and immunization [43]. Also, higher affinity mutants of scFv (single-chain fragment variable) can be generated through site-directed mutagenesis which is much easier and simpler to be performed [50, 116]. In contrast to soluble scFv (single-chain fragment variable), phage-displayed scFv (single-chain fragment variable) can be used directly during mice immunization to produce anti-idiotypic antibodies without the use of adjuvants. This is because phage particles are also good immunogens [117].

8. Application of Single-Chain Fragment Variable (scFv) and Phage-Displayed Single-Chain Fragment Variable (scFv)

Since the introduction of hybridoma technology, the exquisite specificity of mAbs and their fusion proteins have been exploited for several applications in medicine, laboratory diagnosis, and research. Recent progress in antibody engineering together with the microbial expression systems could facilitate a powerful tool to design and produce new specificity and tailored antibodies at affordable prices as if for large-scale purposes. Moreover, tags or peptides attached to the antibodies could allow the purification of antibody fragments that can bring homogenous, well-defined, and active proteins.

8.1. Medical Application

In modern medicine, antibodies for therapeutics are well established as an important class of drugs. An antibody in scFv (single-chain fragment variable) format retained the complete antigen-binding capability, thus it could facilitate a potentially unique molecule to be used especially in cancer treatment [118]. In addition, the antibodies with exquisite specificity and affinity towards a specific target have also encouraged their development as delivery vehicles for agents such as radionuclides to target tissues, for radioimmunoimaging and radioimmunotherapy [119, 120].

The small antigen-binding molecule of scFv (single-chain fragment variable) antibodies could offer several advantages over a whole antibody molecule in therapeutic applications [20, 22]. The smaller fragments allow these molecules to penetrate more rapidly and evenly to tumors and other tissue in comparison to the whole antibodies [20, 121]. As these fragments have more rapid clearance from blood, they can be coupled with drugs and radionuclides in order to result in low exposure of the healthy tissue [19, 122, 123]. Besides that, they also found that there was no uptake of the scFv (single-chain fragment variable) by the kidney and they could efficiently localize to the tumors [124]. All these properties are important in cancer therapy. However, contrast idea has been proposed where the small molecular size of scFv (single-chain fragment variable) have the physiological disadvantage of rapid elimination from the body via kidney [125].

Generally, antibody fragments can be utilized for the preparation of immunotoxins, therapeutic gene delivery, and as anticancer intrabodies. Antibody fragments can be fused to a range of toxins such as cytotoxic proteins [126], radionuclides [127], or drugs [128]. Once fused, these immunotoxins could specifically deliver their agents towards cancer antigen-presenting cells. One example of immunotoxin that is currently generated for fatal neoplasm treatment was the fusion of a fully human anti-fAChR Fab-fragment to Pseudomonas exotoxin A to generate an anti-fAChR immunotoxin (scFv35-ETA) [129]. Following this, all the cancer cells are killed upon the immunotoxins being internalized. In addition to targeting the antigen, tumor-specific scFv (single-chain fragment variable) could too deliver promising therapeutic agents such as tumor necrosis factor (TNF) and to be fused to interleukin-2 (IL-2) or superantigen Staphylococcal Enterotoxin B- for T-cell-mediated eradication of tumors [130, 131]. Besides, Certolizumab Pegol that works as an immunoinhibitor to block the TNF-α has been recently approved by FDA to be used for the treatment of Crohn’s disease and rheumatoid arthritis. It was found to be effective on various inflammatory diseases [132]. Efficacy of Certolizumab Pegol was supported by phase III clinical trial which was compared with the placebo [133].

8.1.1. scFv (Single-Chain Fragment Variable) for Crohn’s Disease and Rheumatoid Arthritis

Alternatively, antibody fragments could also play an important role in the gene therapy of cancer. It includes the therapeutic gene delivery applications where the viral and nonviral vector are used. These viral vectors are known to be very efficient in delivering therapeutic genes to target cell populations, but yet, their clinical use may be restricted by eliciting of immune response. While for nonviral vectors, they often lack their specificity in comparison to the viral vectors. Several studies were performed where scFv (single-chain fragment variable) were used in the development of specific viral and nonviral targeting vectors for therapeutic gene delivery. For instance, one study was performed by Kuroki et al. [134] in the development of a retroviral vector that displays anti-CEA-scFv against carcinoembryonic antigen (CEA). At the same time, this vector also brings together the therapeutic gene of nitric oxide synthase. As a result, this recombinant retrovirus can particularly bound, infect and kill the CEA-expressing cancer cells and finally verify cell-specific delivery of the therapeutic gene [134]. Other approach was carried out by Li et al. [135] in which they produced a nonviral vectors carrying anti-ErbB2 scFv (single-chain fragment variable) against a tumor-associated receptor that is overexpressed in most of human cancers (ErbB2). It was showed that these vectors are capable of delivering exogenous DNA into ErbB2 receptor expressing cells compared to cells that do not express these receptors.

Apart from immunotoxins and therapeutic gene delivery, there are also anticancer intrabodies which have been proved not only to be antiviral, but are also known as potent antitumor agents. Numerous studies have reported their ability in expressing within the cell, specifically binding and neutralizing a range of oncogenes together with signaling molecules. It has been found that this process is effective in decreasing tumor growth and in the potential admission of cells into the apoptotic cycle. Lately, there is anti-ErbB2 intrabody which was tested in phase I clinical trials. The treatment involved adenoviral-mediated gene therapy in conjunction with this intrabody and has proven to be possible in the treatment of ErbB2-overexpressing ovarian cancer [136]. Another study conducted by Strube and Chen [137] has proven that anticyclin E scFv (single-chain fragment variable) intrabody which are expressed in the nucleus of the breast cancer cell line could inhibit the growth of this cell line.

Up till now, several mAbs have been approved by the U.S. Food and Drug Administration (FDA) for the cancer treatment (Table 1). However, immunotherapy has been more successful against circulating cancer cells rather than solid tumors since they have greater cell accessibility. This is illustrated by the FDA approval of intact antibodies such as Rituxan, for the treatment of non-Hodgkin lymphoma and Campath and Mylotarg for the treatments of leukemia (Table 1) [138]. There only two monoclonal antibodies have been approved previously for the treatment of solid tumors which are Herceptin, for the treatment of breast carcinoma and PanoRex for colon cancer. Even though the mechanisms of action are still under investigation, Herceptin appears to make use of Fc receptors and angiogenesis [139], while Rituxan triggers apoptosis throughout receptor dimerization [140].

Table 1: FDA-approved therapeutic antibodies [3].

Brand name
Antibody
Target
Source
Year
Indication

Orthoclone®
Muromonab-CD3
CD3
All rodent
1986
Transplantation rejection

ReoProTM
Abciximab
GPIIb, IIIa
Chimeric
1994
High-risk angioplasty

RituxanTM
Rituximab
CD20
Chimeric
1994
Non-Hodgkin’s lymphoma, rheumatoid arthritis

Zenapax®
Daclizumab
CD25
Humanized
1997
Transplantation rejection

REMICADE®
Infliximab
TNF-a
Chimeric
1998
Crohn’s disease

Simulect®
Basiliximab
CD25
Chimeric
1998
Transplantation rejection

SynagisTM
Palivizumab
RSV F protein
Humanized
1998
RSV infection

Herceptin®
Trastuzumab
HER-2
Humanized
1998
Breast cancer

MylotargTM
Gemtuzumab
CD33
Humanized
2000
Acute Myeloid Leukemia

Campath®
Alemtuzumab
CD52
Humanized
2001
Chronic lymphotic leucemia, T-cell lymphoma

Zevalin®
Ibritumomab tiuxetan
CD20
Murine—with yttrium-90 or indium-111
2002
Non-Hodgkin’s lymphoma

HUMIRATM
Adalimumab
TNF-a
Human
2002
Inflammatory diseases: mostly autoimmune disorders like rheumatoid arthritis, psoriadic arthritis, Morbus Chron

Bexxar®
Tositumomab
CD20
Murine: covalentely bound to Iodine 131
2003
Non-Hodgkin’s lymphoma

Xolair®
Omalizumab
IgE
Humanized
2003
Severe (allergic) asthma

AvastinTM
Bevacizumab
VEGF
Humanized
2004
Metastatic colorectal cancer, nonsmall cell lung cancer, metastatic breast cancer

TYSABRI®
Natalizumab
α4 subunit of a4β1
Humanized
2004
Multiple Sclerosis, Chron’s disease

ErbituxTM
Cetuximab
EGFR
Chimeric
2004
Colorectal cancer, head and neck cancer

VectibixTM
Panitumumab
EGFR
Human
2006
Metastatic colorectal carcinoma

LUCENTISTM
Ranibizumab
VEGF-A
Humanized Fab
2006
Wet macular degeneration

Soliris®
Eculizumab
CD59
Humanized
2007
Paroxysmal nocturnal hemoglobinuria

CIMZIA®
Certolizumab pegol
TNF-a
Humanized (Fab)
2008
Crohn’s disease, rheumatoid arthritis

SimponiTM
Golimumab
TNF-a
Human
2009
Rheumatoid and psoriatic arthritis, active ankylosing spondylitis

Since September 1998, Herceptin (Trastuzumab) has been approved for the treatment of HER2-positive metastatic breast cancer. This first humanized antibody ws then approved for the second time in November 2006 as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel, for the adjuvant treatment of patients with HER2-positive, node-positive breast cancer. Basically, Herceptin is designed to target and block the function of HER2 protein overexpression [141]. Research has shown that HER2-positive breast cancer is a more aggressive disease with greater chances of recurrence, a poorer prognosis, and a reduced chance of survival in comparison to HER2-negative breast cancer.

The most recent study was performed by Koido et al. [142] which suggest that tumor-cell lines (MCF-7) can be used as a fusion partner in the development of dendritic cell (DC) tumor fusion vaccine. Once successfully fused, they can be served as a vaccine for active immunotherapy or as stimulators to activate and expand T cells for adoptive immunotherapy applications. In separate study, McWhirter et al. [98] has produced cell-surface-associated proteins that overexpressed on B-cell chronic lymphocytic leukemia (CLL) which could serve as therapeutic antibody targets by encouraging a cytotoxic T-cell response.

8.2. Diagnostic Application

Another important application of the scFv (single-chain fragment variable) is as diagnostic reagents. During past years, tailor-made recombinant scFv (single-chain fragment variable) antibodies produced in bacteria have become potential alternatives to these “conventional” immunodiagnostic reagents [143]. The functionality of recombinant antibody fragments (scFv) as immunological reagents has been discovered in several different assay formats [144, 145].

In general, monoclonal antibody especially scFv (single-chain fragment variable) antibody for diagnostic purposed can bind to a variety of antigens such as haptens, proteins, and also whole pathogens, and they can as well be used in the enzyme-linked immunosorbent assay (ELISA) [146]. The detection of scFv (single-chain fragment variable) can be done using secondary antibody recognizing specific tag which already fused to the C- or N-terminus of scFv (single-chain fragment variable). A number of tags have been used previously, such as c-myc [147] or E-tag (Pharmacia). Due to improper folding of soluble scFv (single-chain fragment variable), they can be easily inactivated during being coated on the microtiter plates. This was caused by the lack of constant domains of heavy and light chains. In order to overcome this difficulty, (especially during the selection of scFv (single-chain fragment variable) from phage display libraries), scFv (single-chain fragment variable) in a phage format can be used in ELISA assay, which means that the scFv (single-chain fragment variable) is remain attached to the coat protein of filamentous phage. By applying this step, it may improve the protein folding as the phage may mimic missing constant domains of the original antibody [148].

Another approach to this problem is via fusing the scFv (single-chain fragment variable) to other proteins such as constant light chain domain, leucine zipper dimerization domain (ZIP) [149], Fc fragment (CH2 and CH3 domains) of mouse IgG1 [150], and alkaline phosphatase (AP) [151] to become more stable while retaining the functionality. According to Harper et al. [152], the fused scFv (single-chain fragment variable) is considered to direct to the configuration of dimers, which should have better avidity and stability compared to original monovalent scFv (single-chain fragment variable). Furthermore, in the case where scFv (single-chain fragment variable) fused to alkaline phosphatase (AP), there is the possibility of direct detection with substrate without the use of expensive antibody enzyme conjugates [56].

Besides diagnosis, the scFv (single-chain fragment variable) fusion proteins could also provide a valuable tool in controlling infectious disease, whereas phages displaying antibody fragments can be used for antigen detection and recognition in ELISA or immunoblot detection [88]. Moreover, the detection can be easily magnified by fusing a colour-generating enzyme such as alkaline phosphatase to the pVIII protein which was greater copy number compared to the pIII protein [115]. For instance, a sandwich-type ELISA (enzyme-linked immunosorbent assay) was developed by Kerschbaumer et al. [151] based on the scFv (single-chain fragment variable) fusion proteins in both capture and detection of a plant pathogen.

In addition to fusion protein, the new perspectives for exploiting scFv (single-chain fragment variable) have too widely opened with various fluorescent proteins, giving rise to fluobodies. Griep et al. [153] in their study successfully fused scFv (single-chain fragment variable) to a mutant of green fluorescence protein (GFP), followed by expression in E. coli and after that used it for direct labeling in flow cytometry and immunofluorescence experiments. This fluobodies do not fade after illumination in comparison to fluorochrome-fluorescein-isothiocyanate- (FITC-) conjugated antibodies. In a different report, scFv (single-chain fragment variable) antibodies were fused with different wavelengths of fluorescent proteins to permit concurrent multicoloured staining with antibodies against different antigens [154]. Alternatively, fluobodies were also utilized in a novel assay, called fluorophor-linked immunosorbent assay (FLISA) which is similar to ELISA. Theoretically, scFv (single-chain fragment variable) is fused to a fluorescent protein and antigen binding is detected by measuring the fluorescence. It thus make this assay faster and simpler than the comparable ELISA, and circumvent the need of secondary antibodies [155].

Overall, scFv (single-chain fragment variable) demonstrated to be valuable reagents in both detection and diagnostics. With new phage display antibody libraries, one can generate a range of scFv (single-chain fragment variable) specifically directed against any antigen economically, quickly, and without the bother of immunizing animals and manipulating hybridomas.

8.3. Potential Application of Single-Chain Variable Fragment (scFv) in Breast Cancer Studies

Breast cancer is a malignant tumor that has developed beginning from cells of the breast. A malignant tumor is a group of cancer cells that may attack adjacent tissues or spread (metastasize) to distant areas of the body. Nowadays, breast cancer is the most common and frequent cause of cancer-derived death in women [156]. There are conventional therapies such as surgery, chemotherapy, radiotherapy, antiestrogen therapy which are not able to eliminate occult cancer cells and therefore to prevent metastatic diseases, relapses, and bears the risk of side effects on non-tumor tissues [157]. Therefore, sensitive detection of residual cancer cells in breast tissue may have important therapeutic and prognostic implications. The potential targets for immunotherapy could be achieved by identification of tumorspecific or associated antigens on the surface of breast cancer cells [158]. The first promising approaches which have been published in immunotherapy involve the application of monoclonal antibodies, immunotoxins, bispecific antibodies, or vaccination with tumor-specific antigens [159, 160]. Until now, recombinant antibody fragments have been proven promising in vitro as well as in phase I and II clinical trials in certain types of cancer [161, 162]. Nevertheless, antigens suitable for immunotherapy in breast cancer are still rare.

A fusion between the lymphocytes of Balb/c mice sensitized with the MCF-7 breast carcinoma cell line with Sp2 myeloma cells [163]. From this study, the mouse hybridoma clone (C3A8) established was very stable in secreting monoclonal antibody. mAbs produced by C3A8 reacted very strongly to the human breast cancer cell lines MCF-7 and T47-D but showed negligible reactivity against other human cancer cell lines and series of normal tissues [163, 164]. The C3A8 clone showed 100% positivity after five limiting dilutions and secreted IgM Mab with kappa light chain. An immunohistological study performed by these researchers showed that the Mab reacted to lobular breast and fibroadenoma cancer tissues at the cytoplasmic region. While the reactivity of Mab C3A8 towards MCF-7 cell line was markedly reduced by trypsin but not to periodate or neuraminidase. Therefore, the epitope recognized by Mab C3A8 is not a carbohydrate or glycoprotein but an endopeptide consisting of arginine and lysine side chains.

Studies on the binding activities of monoclonal antibody to breast cancer and antigenic sites of the MCF-7 could be performed using the scFv (single-chain fragment variable) because it is highly immunogenic and has distinct antigens that elicit antibodies specific for this type of cancer [165–167]. For instance, in site-directed mutagenesis, the important variable regions or residues involved in binding activity could be determined and mutants with higher affinity can be created. This is particularly important for improvement of the performance of clinical assays for MCF-7 breast cancer cells. Besides, the smaller molecules of scFv (single-chain fragment variable) could as well facilitate crystallographic study of MCF-7 cells-antibody interaction. All these applications can be carried out with much ease on small molecules like scFv (single-chain fragment variable) than the intact IgM molecule. In addition, since the bacteriophages are highly immunogenic [117], mice immunized with the phage-displayed scFv (single-chain fragment variable) could produce anti-idiotypic antibodies which are required for receptor studies of MCF-7 breast cancer cells.

9. Conclusion

mAbs in scFv (single-chain fragment variable) format is preferred than intact antibodies due to its smaller size and less possibility of developing antimouse antibody response. Besides, it is possible to be designed as bispecific antibody to work as immunotoxin. It thus makes scFv (single-chain fragment variable) as the best candidate for medical, diagnostic and research applications. As mentioned in this review, range of antibodies fragments can be expressed in E. coli as active antigen-binding proteins. However, the levels of scFv (single-chain fragment variable) expression may widely vary. Therefore, several factors and parameters should be optimized to improve functional of each scFv (single-chain fragment variable) antibody expression as well as better antigen-binding affinity.

References

C. A. Janeway, P. Travers, M. Walport, et al., Immunobiology, Garland Publishing, 5th edition, 2001.

I. B. Rogozin, V. V. Solovyov, and N. A. Kolchanov, “Somatic hypermutagenesis in immunoglobulin genes. I. Correlation between somatic mutations and repeats. Somatic mutation properties and clonal selection,” Biochimica et Biophysica Acta, vol. 1089, no. 2, pp. 175–182, 1991.

D. S. Dimitrov and J. D. Marks, “Therapeutic antibodies: current state and future trends—is a paradigm change coming soon?” Methods in Molecular Biology, vol. 525, pp. 1–27, 2009.

M. A. Boss, J. H. Kenten, C. R. Wood, and J. S. Emtage, “Assembly of functional antibodies from immunoglobulin heavy and light chains synthesised in Escherichia coli,” Nucleic Acids Research, vol. 12, no. 9, pp. 3791–3806, 1984.

R. E. Kontermann and R. Müller, “Intracellular and cell surface displayed single-chain diabodies,” Journal of Immunological Methods, vol. 226, no. 1-2, pp. 179–188, 1999.

H. Gram, L. A. Marconi, C. F. Barbas, T. A. Collet, R. A. Lerner, and A. S. Kang, “in vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 8, pp. 3576–3580, 1992.

A. Klimka, B. Matthey, R. C. Roovers et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning,” British Journal of Cancer, vol. 83, no. 2, pp. 252–260, 2000.

N. A. Watkins and W. H. Ouwehand, “Introduction to antibody engineering and phage display,” Vox Sanguinis, vol. 78, no. 2, pp. 72–79, 2000.

V. Feys, P. de Waele, A. van de Voorde, P. Casneuf, and W. Fiers, “Expression of functional mouse antibodies directed against the tumour marker human placental alkaline phosphatase in non-lymphoid cells,” International Journal of Cancer, vol. 41, no. 2, pp. 26–27, 1988.

S. J. M. O'Connor, P. D. Forsyth, S. Dalal et al., “The rapid diagnosis of acute promyelocytic leukaemia using PML (5E10) monoclonal antibody,” British Journal of Haematology, vol. 99, no. 3, pp. 597–604, 1997.

S. Cabilly, A. D. Riggs, and H. Pande, “Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 11 I, pp. 3273–3277, 1984.

A. Skerra and A. Plückthun, “Assembly of a functional immunoglobulin Fv fragment in Escherichia coli,” Science, vol. 240, no. 4855, pp. 1038–1041, 1988.

M. Better, C. P. Chang, R. R. Robinson, and A. H. Horwitz, “Escherichia coli secretion of an active chimeric antibody fragment,” Science, vol. 240, no. 4855, pp. 1041–1043, 1988.

J. McCafferty, A. D. Griffiths, G. Winter, and D. J. Chiswell, “Phage antibodies: filamentous phage displaying antibody variable domains,” Nature, vol. 348, no. 6301, pp. 552–554, 1990.

M. Ho, S. Nagata, and I. Pastan, “Isolation of anti-CD22 Fv with high affinity by Fv display on human cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 25, pp. 9637–9642, 2006.

P. Galeffi, A. Lombardi, I. Pietraforte et al., “Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems,” Journal of Translational Medicine, vol. 4, article no. 39, 2006.

A. B. H. Choo, R. D. Dunn, K. W. Broady, and R. L. Raison, “Soluble expression of a functional recombinant cytolytic immunotoxin in insect cells,” Protein Expression and Purification, vol. 24, no. 3, pp. 338–347, 2002.

J. S. Huston, A. J. T. George, G. P. Adams et al., “Single-chain Fv radioimmunotargeting,” Quarterly Journal of Nuclear Medicine, vol. 40, no. 3, pp. 320–333, 1996.

S. Dana Jones and W. A. Marasco, “Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression,” Advanced Drug Delivery Reviews, vol. 31, no. 1-2, pp. 153–170, 1998.

D. Colcher, G. Pavlinkova, G. Beresford, B. J. M. Booth, A. Choudhury, and S. K. Batra, “Pharmacokinetics and biodistribution of genetically-engineered antibodies,” Quarterly Journal of Nuclear Medicine, vol. 42, no. 4, pp. 225–241, 1998.

P. J. Hudson, “Recombinant antibody fragments,” Current Opinion in Biotechnology, vol. 9, no. 4, pp. 395–402, 1998.

P. J. Hudson, “Recombinant antibody constructs in cancer therapy,” Current Opinion in Immunology, vol. 11, no. 5, pp. 548–557, 1999.

M. Little, S. M. Kipriyanov, F. Le Gall, and G. Moldenhauer, “Of mice and men: hybridoma and recombinant antibodies,” Immunology Today, vol. 21, no. 8, pp. 364–370, 2000.

M. Hust, T. Jostock, C. Menzel et al., “Single chain Fab (scFab) fragment,” BMC Biotechnology, vol. 7, article no. 14, 2007.

R. Glockshuber, M. Malia, I. Pfitzinger, and A. Plückthun, “A comparison of strategies to stabilize immunoglobulin Fv-fragments,” Biochemistry, vol. 29, no. 6, pp. 1362–1367, 1990.

K. Petrov, M. Dion, L. Hoffmann, T. Dintinger, A. Defontaine, and C. Tellier, “Bivalent Fv antibody fragments obtained by substituting the constant domains of a fab fragment with heterotetrameric molybdopterin synthase,” Journal of Molecular Biology, vol. 341, no. 4, pp. 1039–1048, 2004.

M. Furuta, M. Uchikawa, Y. Ueda et al., “Construction of mono- and bivalent human single-chain Fv fragments against the D antigen in the Rh blood group: multimerization effect on cell agglutination and application to blood typing,” Protein Engineering, vol. 11, no. 3, pp. 233–241, 1998.

P. J. Hudson and A. A. Kortt, “High avidity scFv multimers; diabodies and triabodies,” Journal of Immunological Methods, vol. 231, no. 1-2, pp. 177–189, 1999.

A. Pluckthun and P. Pack, “New protein engineering approaches to multivalent and bispecific antibody fragments,” Immunotechnology, vol. 3, no. 2, pp. 83–105, 1997.

A. D. Griffiths and A. R. Duncan, “Strategies for selection of antibodies by phage display,” Current Opinion in Biotechnology, vol. 9, no. 1, pp. 102–108, 1998.

J. S. Huston, M. Mudgett-Hunter, M. S. Tai et al., “Protein engineering of single-chain Fv analogs and fusion proteins,” Methods in Enzymology, vol. 203, pp. 46–88, 1991.

R. E. Bird, K. D. Hardman, J. W. Jacobson et al., “Single-chain antigen-binding proteins,” Science, vol. 241, no. 4877, pp. 423–426, 1988.

K. Takkinen, M. L. Laukkanen, D. Sizmann et al., “An active single-chain antibody containing a cellulase linker domain is secreted by Escherichia coli,” Protein Engineering, vol. 4, no. 7, pp. 837–841, 1991.

J. E. Smallshaw, F. Georges, J. S. Lee, and E. B. Waygood, “Synthesis, cloning and expression of the single-chain Fv gene of the HPr-specific monoclonal antibody, Jel42. Determination of binding constants with wild-type and mutant HPrs,” Protein Engineering, vol. 12, no. 7, pp. 623–630, 1999.

P. Argos, “An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion,” Journal of Molecular Biology, vol. 211, no. 4, pp. 943–958, 1990.

M. Whitlow, B. A. Bell, S. L. Feng et al., “An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability,” Protein Engineering, vol. 6, no. 8, pp. 989–995, 1993.

J. S. Huston, D. Levinson, M. Mudgett-Hunter et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 16, pp. 5879–5883, 1988.

V. K. Chaudhary, J. K. Batra, M. G. Gallo, M. C. Willingham, D. J. FitzGerald, and I. Pastan, “A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 3, pp. 1066–1070, 1990.

X. K. Deng, L. A. Nesbit, and K. J. Morrow Jr., “Recombinant single-chain variable fragment antibodies directed against Clostridium difficile toxin B produced by use of an optimized phage display system,” Clinical and Diagnostic Laboratory Immunology, vol. 10, no. 4, pp. 587–595, 2003.

T. Clackson, H. R. Hoogenboom, A. D. Griffiths, and G. Winter, “Making antibody fragments using phage display libraries,” Nature, vol. 352, no. 6336, pp. 624–628, 1991.

V. K. Chaudhary, C. Queen, R. P. Junghans, T. A. Waldmann, D. J. FitzGerald, and I. Pastan, “A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin,” Nature, vol. 339, no. 6223, pp. 394–397, 1989.

W. J. J. Finlay, L. Shaw, J. P. Reilly, and M. Kane, “Generation of high-affinity chicken single-chain Fv antibody fragments for measurement of the Pseudonitzschia pungens toxin domoic acid,” Applied and Environmental Microbiology, vol. 72, no. 5, pp. 3343–3349, 2006.

J. D. Marks, H. R. Hoogenboom, T. P. Bonnert, J. McCafferty, A. D. Griffiths, and G. Winter, “By-passing immunization: human antibodies from V-gene libraries displayed on phage,” Journal of Molecular Biology, vol. 222, no. 3, pp. 581–597, 1991.

M. Shadidi and M. Sioud, “An anti-leukemic single chain fv antibody selected from a synthetic human phage antibody library,” Biochemical and Biophysical Research Communications, vol. 280, no. 2, pp. 548–552, 2001.

J. L. Zhang, J. J. Guo, Z. Y. Zhang et al., “Screening and evaluation of human single-chain fragment variable antibody against hepatitis B virus surface antigen,” Hepatobiliary and Pancreatic Diseases International, vol. 5, no. 2, pp. 237–241, 2006.

K. Dai, H. Zhu, and C. Ruan, “Generation and characterization of recombinant single chain Fv antibody that recognizes platelet glycoprotein Ibα,” Thrombosis Research, vol. 109, no. 2-3, pp. 137–144, 2003.

X. Hu, R. O'Dwyer, and J. G. Wall, “Cloning, expression and characterisation of a single-chain Fv antibody fragment against domoic acid in Escherichia coli,” Journal of Biotechnology, vol. 120, no. 1, pp. 38–45, 2005.

A. Sheikholvaezin, P. Sandström, D. Eriksson, N. Norgren, K. Riklund, and T. Stigbrand, “Optimizing the generation of recombinant single-chain antibodies against placental alkaline phosphatase,” Hybridoma, vol. 25, no. 4, pp. 181–192, 2006.

D. Luo, N. Mah, M. Krantz et al., “VI-linker-Vh orientation-dependent expression of single chain Fv containing an engineered disulfide-stabilized bond in the framework regions,” Journal of Biochemistry, vol. 118, no. 4, pp. 825–831, 1995.

D. F. Lake, K. S. Lam, L. Peng, and E. M. Hersh, “Molecular cloning, expression and mutagenesis of an anti-insulin single chain Fv (scFv),” Molecular Immunology, vol. 31, no. 11, pp. 845–856, 1994.

R. M. Horton, H. D. Hunt, S. N. Ho, J. K. Pullen, and L. R. Pease, “Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension,” Gene, vol. 77, no. 1, pp. 61–68, 1989.

R. D. LeBoeuf, F. S. Galin, S. K. Hollinger, S. C. Peiper, and J. E. Blalock, “Cloning and sequencing of immunoglobulin variable-region genes using degenerate oligodeoxyribonucleotides and polymerase chain reaction,” Gene, vol. 82, no. 2, pp. 371–377, 1989.

G. G. Lilley, O. Dolezal, C. J. Hillyard, C. Bernard, and P. J. Hudson, “Recombinant single-chain antibody peptide conjugates expressed in Escherichia coli for the rapid diagnosis of HIV,” Journal of Immunological Methods, vol. 171, no. 2, pp. 211–226, 1994.

H. H. Hogrefe, R. L. Mullinax, A. E. Lovejoy, B. N. Hay, and J. A. Sorge, “A bacteriophage lambda vector for the cloning and expression of immunoglobulin Fab fragments on the surface of filamentous phage,” Gene, vol. 128, no. 1, pp. 119–126, 1993.

N. Kobayashi, M. Ohtoyo, E. Wada, Y. Kato, N. Mano, and J. Goto, “Generation of a single-chain Fv fragment for the monitoring of deoxycholic acid residues anchored on endogenous proteins,” Steroids, vol. 70, no. 4, pp. 285–294, 2005.

C. D. Martin, G. Rojas, J. N. Mitchell et al., “A simple vector system to improve performance and utilisation of recombinant antibodies,” BMC Biotechnology, vol. 6, article no. 46, 2006.

P. L. Wang, B. K. C. Lo, and G. Winter, “Generating molecular diversity by homologous recombination in Escherichia coli,” Protein Engineering, Design and Selection, vol. 18, no. 8, pp. 397–404, 2005.

J. Q. Guo, S. Y. You, L. Li, Y. Z. Zhang, J. N. Huang, and C. Y. Zhang, “Construction and high-level expression of a single-chain Fv antibody fragment specific for acidic isoferritin in Escherichia coli,” Journal of Biotechnology, vol. 102, no. 2, pp. 177–189, 2003.

P. Ravn, A. Danielczyk, K. Bak Jensen et al., “Multivalent scFv display of phagemid repertoires for the selection of carbohydrate-specific antibodies and its application to the Thomsen-Friedenreich antigen,” Journal of Molecular Biology, vol. 343, no. 4, pp. 985–996, 2004.

K. Sakai, Y. Shimizu, T. Chiba et al., “Isolation and characterization of phage-displayed single chain antibodies recognizing nonreducing terminal mannose residues. 1. A new strategy for generation of anti-carbohydrate antibodies,” Biochemistry, vol. 46, no. 1, pp. 253–262, 2007.

J. He, G. Zhou, K. D. Liu, and X. Y. Qin, “Construction and preliminary screening of a human phage single-chain antibody library associated with gastric cancer,” Journal of Surgical Research, vol. 102, no. 2, pp. 150–155, 2002.

R. Verma, E. Boleti, and A. J. T. George, “Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems,” Journal of Immunological Methods, vol. 216, no. 1-2, pp. 165–181, 1998.

F. Baneyx, “Recombinant protein expression in Escherichia coli,” Current Opinion in Biotechnology, vol. 10, no. 5, pp. 411–421, 1999.

C. W. Goulding and L. J. Perry, “Protein production in Escherichia coli for structural studies by X-ray crystallography,” Journal of Structural Biology, vol. 142, no. 1, pp. 133–143, 2003.

J. R. Swartz, “Advances in Escherichia coli production of therapeutic proteins,” Current Opinion in Biotechnology, vol. 12, no. 2, pp. 195–201, 2001.

F. J.M. Mergulhão, G. A. Monteiro, J. M.S. Cabral, and M. A. Taipa, “Design of bacterial vector systems for the production of recombinant proteins in Escherichia coli,” Journal of Microbiology and Biotechnology, vol. 14, no. 1, pp. 1–14, 2004.

R. K. C. Knaust and P. Nordlund, “Screening for soluble expression of recombinant proteins in a 96-well format,” Analytical Biochemistry, vol. 297, no. 1, pp. 79–85, 2001.

S. A. Lesley, “High-throughput proteomics: protein expression and purification in the postgenomic world,” Protein Expression and Purification, vol. 22, no. 2, pp. 159–164, 2001.

A. Pluckthun, “Antibody engineering,” Current Opinion in Biotechnology, vol. 2, no. 2, pp. 238–246, 1991.

J. Buchner and R. Rudolph, “Routes to active proteins from transformed microorganisms,” Current Opinion in Biotechnology, vol. 2, no. 4, pp. 532–538, 1991.

J. S. Huston, A. J. T. George, M. S. Tai, et al., “Single-chain Fv design and production by preparative folding,” in Antibody Engineering, C. A. Borrebaeck, Ed., pp. 185–227, Oxford University Press, New York, NY, USA, 1995.

H. Bothmann and A. Plückthun, “The periplasmic Escherichia coli peptidylprolyl cis,trans-isomerase FkpA: I. Increased functional expression of antibody fragments with and without cis-prolines,” Journal of Biological Chemistry, vol. 275, no. 22, pp. 17100–17105, 2000.

H. Bothmann and A. Plückthun, “Selection for a periplasmic factor improving phage display and functional periplasmic expression,” Nature Biotechnology, vol. 16, no. 4, pp. 376–380, 1998.

K. Ramm and A. Plückthun, “The periplasmic Escherichia coli peptidylprolyl cis,trans-isomerase FkpA: II. Isomerase-independent chaperone activity in vitro,” Journal of Biological Chemistry, vol. 275, no. 22, pp. 17106–17113, 2000.

S. M. Aavula, S. V. Nimmagadda, N. Biradhar, et al., “Generation and characterization of an scFv directed against site II of Rabies Glycoprotein,” Biotechnology Research International, vol. 2011, Article ID 652147, 11 pages, 2011.

L. Nieba, A. Honegger, C. Krebber, and A. Plückthun, “Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment,” Protein Engineering, vol. 10, no. 4, pp. 435–444, 1997.

A. Wörn and A. Plückthun, “An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly,” FEBS Letters, vol. 427, no. 3, pp. 357–361, 1998.

G. P. Smith, “Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface,” Science, vol. 228, no. 4705, pp. 1315–1317, 1985.

C. C. Wu, E. H. Lin, Y. C. Lee et al., “Identification of a new peptide for fibrosarcoma tumor targeting and imaging in vivo,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 167045, 10 pages, 2010.

W. H. Wieland, D. Orzáez, A. Lammers, H. K. Parmentier, and A. Schots, “Display and selection of chicken IgA Fab fragments,” Veterinary Immunology and Immunopathology, vol. 110, no. 1-2, pp. 129–140, 2006.

S. I. Takemura, R. Asano, K. Tsumoto et al., “Construction of a diabody (small recombinant bispecific antibody) using a refolding system,” Protein Engineering, vol. 13, no. 8, pp. 583–588, 2000.

L. Xu, B. Q. Jin, and D. M. Fan, “Selection and identification of mimic epitopes for gastric cancer-associated antigen MG7 Ag,” Molecular Cancer Therapeutics, vol. 2, no. 3, pp. 301–306, 2003.

F. Rahbarizadeh, M. J. Rasaee, M. Forouzandeh Moghadam, A. A. Allameh, and E. Sadroddiny, “Production of novel recombinant single-domain antibodies against tandem repeat region of MUC1 mucin,” Hybridoma and Hybridomics, vol. 23, no. 3, pp. 151–159, 2004.

K. Charlton, W. J. Harris, and A. J. Porter, “The isolation of super-sensitive anti-hapten antibodies from combinatorial antibody libraries derived from sheep,” Biosensors and Bioelectronics, vol. 16, no. 9-12, pp. 639–646, 2001.

T. Okada, M. Akada, T. Fujita et al., “A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers,” Clinical Cancer Research, vol. 12, no. 1, pp. 191–197, 2006.

T. J. Vaughan, A. J. Williams, K. Pritchard et al., “Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library,” Nature Biotechnology, vol. 14, no. 3, pp. 309–314, 1996.

M. D. Sheets, P. Amersdorfer, R. Finnern et al., “Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 11, pp. 6157–6162, 1998.

G. Winter, A. D. Griffiths, R. E. Hawkins, and H. R. Hoogenboom, “Making antibodies by phage display technology,” Annual Review of Immunology, vol. 12, pp. 433–455, 1994.

A. D. Griffiths, S. C. Williams, O. Hartley et al., “Isolation of high affinity human antibodies directly from large synthetic repertoires,” EMBO Journal, vol. 13, no. 14, pp. 3245–3260, 1994.

A. Knappik, L. Ge, A. Honegger et al., “Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides,” Journal of Molecular Biology, vol. 296, no. 1, pp. 57–86, 2000.

T. Völkel, R. Müller, and R. E. Kontermann, “Isolation of endothelial cell-specific human antibodies from a novel fully synthetic scFv library,” Biochemical and Biophysical Research Communications, vol. 317, no. 2, pp. 515–521, 2004.

J. Hanes and A. Plückthun, “In vitro selection and evolution of functional proteins by using ribosome display,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 10, pp. 4937–4942, 1997.

J. Hanes, C. Schaffitzel, A. Knappik, and A. Plückthun, “Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display,” Nature Biotechnology, vol. 18, no. 12, pp. 1287–1292, 2000.

A. S. Kang, C. F. Barbas, K. D. Janda, S. J. Benkovic, and R. A. Lerner, “Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 10, pp. 4363–4366, 1991.

H. R. Hoogenboom and P. Chames, “Natural and designer binding sites made by phage display technology,” Immunology Today, vol. 21, no. 8, pp. 371–378, 2000.

H. R. Hoogenboom, A. P. De Brune, S. E. Hufton, R. M. Hoet, J. W. Arends, and R. C. Roovers, “Antibody phage display technology and its applications,” Immunotechnology, vol. 4, no. 1, pp. 1–20, 1998.

B. Yuan, P. Schulz, R. Liu, and M. R. Sierks, “Improved affinity selection using phage display technology and off-rate based selection,” Electronic Journal of Biotechnology, vol. 9, no. 2, pp. 171–175, 2006.

J. R. McWhirter, A. Kretz-Rommel, A. Saven et al., “Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 4, pp. 1041–1046, 2006.

R. E. Hawkins, S. R. Russel, and G. Winter, “Selection of phage antibodies of a structural epitope by using a peptide library displayed on filamentous bacteriophage,” Journal of Immunology, vol. 153, pp. 724–729, 1992.

R. Schier, J. Bye, G. Apell et al., “Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection,” Journal of Molecular Biology, vol. 255, no. 1, pp. 28–43, 1996.

P. Jurado, V. De Lorenzo, and L. A. Fernández, “Thioredoxin fusions increase folding of single chain Fv antibodies in the cytoplasm of Escherichia coli: evidence that chaperone activity is the prime effect of thioredoxin,” Journal of Molecular Biology, vol. 357, no. 1, pp. 49–61, 2006.

M. Dueñas, L. -T. Chin, A. -C. Malmborg, R. Casalvilla, M. Ohlin, and C. A.K. Borrebaeck, “in vitro immunization of naive human B cells yields high affinity immunuglobulin G antibodies as illustrated by phage display,” Immunology, vol. 89, no. 1, pp. 1–7, 1996.

A. Hemminki, S. Niemi, A. M. Hoffrén, L. Hakalahti, H. Söderlund, and K. Takkinen, “Specificity improvement of a recombinant anti-testosterone Fab fragment by CDRIII mutagenesis and phage display selection,” Protein Engineering, vol. 11, no. 4, pp. 311–319, 1998.

C. Krebber, S. Spada, D. Desplancq, and A. Pluckthun, “Co-selection of cognate antibody-antigen pairs by selectively-infective phages,” FEBS Letters, vol. 377, no. 2, pp. 227–231, 1995.

F. Hennecke, C. Krebber, and A. Plückthun, “Non-repetitive single-chain Fv linkers selected by selectively infective phage (SIP) technology,” Protein Engineering, vol. 11, no. 5, pp. 405–410, 1998.

P. Lindner, K. Bauer, A. Krebber et al., “Specific detection of His-tagged proteins with recombinant anti-His tag scfv-phosphatase or scFv-phage fusions,” BioTechniques, vol. 22, no. 1, pp. 140–149, 1997.

A. Klimka, S. Barth, B. Matthey et al., “An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFV)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line,” British Journal of Cancer, vol. 80, no. 8, pp. 1214–1222, 1999.

A. Lekkerkerker and T. Logtenberg, “Phage antibodies against human dendritic cell subpopulations obtained by flow cytometry-based selection on freshly isolated cells,” Journal of Immunological Methods, vol. 231, no. 1-2, pp. 53–63, 1999.

R. J. Giordano, M. Cardó-Vila, J. Lahdenranta, R. Pasqualini, and W. Arap, “Biopanning and rapid analysis of selective interactive ligands,” Nature Medicine, vol. 7, no. 11, pp. 1249–1253, 2001.

R. Beers, P. Chowdhury, D. Bigner, and I. Pastan, “Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display,” Clinical Cancer Research, vol. 6, no. 7, pp. 2835–2843, 2000.

S. G. Park, J. S. Lee, E. Y. Je, I. J. Kim, J. H. Chung, and I. H. Choi, “Affinity maturation of natural antibody using a chain shuffling technique and the expression of recombinant antibodies in Escherichia coli,” Biochemical and Biophysical Research Communications, vol. 275, no. 2, pp. 553–557, 2000.

A. D. Griffiths, M. Malmqvist, J. D. Marks et al., “Human anti-self antibodies with high specificity from phage display libraries,” EMBO Journal, vol. 12, no. 2, pp. 725–734, 1993.

P. Forrer, S. Jung, and A. Plückthun, “Beyond binding: using phage display to select for structure, folding and enzymatic activity in proteins,” Current Opinion in Structural Biology, vol. 9, no. 4, pp. 514–520, 1999.

J. B. Burritt, C. W. Bond, K. W. Doss, and A. J. Jesaitis, “Filamentous phage display of oligopeptide libraries,” Analytical Biochemistry, vol. 238, no. 1, pp. 1–13, 1996.

L. F. Wang, M. Yu, and B. T. Eaton, “Epitope mapping and engineering using phage display technology,” Asia-Pacific Journal of Molecular Biology and Biotechnology, vol. 3, pp. 240–258, 1995.

J. Sharon, “Structural correlates of high antibody affinity: three engineered amino acid substitutions can increase the affinity of an anti-p-azophenylarsonate antibody 200-fold,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 12, pp. 4814–4817, 1990.

A. E. Willis, R. N. Perham, and D. Wraith, “Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage,” Gene, vol. 128, no. 1, pp. 79–83, 1993.

K. Chester, B. Pedley, B. Tolner et al., “Engineering antibodies for clinical applications in cancer,” Tumor Biology, vol. 25, no. 1-2, pp. 91–98, 2004.

D. M. Goldenberg, “Targeted therapy of cancer with radiolabeled antibodies,” Journal of Nuclear Medicine, vol. 43, no. 5, pp. 693–713, 2002.

P. J. Hudson and C. Souriau, “Engineered antibodies,” Nature Medicine, vol. 9, no. 1, pp. 129–134, 2003.

T. Yokota, D. E. Milenic, M. Whitlow, and J. Schlom, “Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms,” Cancer Research, vol. 52, no. 12, pp. 3402–3408, 1992.

N. Oriuchi, T. Higuchi, H. Hanaoka, Y. Iida, and K. Endo, “Current status of cancer therapy with radiolabeled monoclonal antibody,” Annals of Nuclear Medicine, vol. 19, no. 5, pp. 355–365, 2005.

E. Stipsanelli and P. Valsamaki, “Monoclonal antibodies: old and new trends in breast cancer imaging and therapeutic approach,” Hellenic Journal of Nuclear Medicine, vol. 8, no. 2, pp. 103–108, 2005.

M. K. Kim, H. J. Jeong, C. H. K. Kao et al., “Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications,” Nuclear Medicine and Biology, vol. 29, no. 2, pp. 139–146, 2002.

M. D. Winthrop, S. J. DeNardo, H. Albrecht et al., “Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy,” Clinical Cancer Research, vol. 9, no. 10, pp. 3845S–3853S, 2003.

P. S. Chowdhury, J. L. Viner, R. Beers, and I. Pastan, “Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 2, pp. 669–674, 1998.

S. Y. Liu, J. F. Eary, S. H. Petersdorf et al., “Follow-up of relapsed B-cell lymphoma patients treated with iodine-131- labeled anti-CD20 antibody and autologous stem-cell rescue,” Journal of Clinical Oncology, vol. 16, no. 10, pp. 3270–3278, 1998.

R. V. J. Chari, “Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy,” Advanced Drug Delivery Reviews, vol. 31, no. 1-2, pp. 89–104, 1998.

S. Gattenlöhner, H. Jörissen, M. Huhn et al., “A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 187621, 11 pages, 2010.

Q. Tong, K. Liu, X. M. Lu, et al., “Construction and characterization of a novel fusion protein MG7-scFv/SEB against gastric cancer,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 121094, 8 pages, 2010.

N. J. V. Hansen, L. S. Pedersen, A. Stryhn, and S. Buus, “In situ cytokine therapy: redistribution of clonally expanded T cells,” European Journal of Immunology, vol. 31, no. 1, pp. 250–258, 2001.

W. Kaushik and R. J. Moots, “CDP-870 (certolizumab) in rheumatoid arthritis,” Expert Opinion on Biological Therapy, vol. 5, no. 4, pp. 601–606, 2005.

W. J. Sandborn, B. G. Feagan, S. Stoinov et al., “Certolizumab pegol for the treatment of Crohn's disease,” New England Journal of Medicine, vol. 357, no. 3, pp. 228–238, 2007.

M. Kuroki, F. Arakawa, P. D. Khare et al., “Specific targeting strategies of cancer gene therapy using a single-chain variable fragment (scFv) with a high affinity for CEA,” Anticancer Research, vol. 20, no. 6 A, pp. 4067–4071, 2000.

X. Li, P. Stuckert, I. Bosch, J. D. Marks, and W. A. Marasco, “Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells,” Cancer Gene Therapy, vol. 8, no. 8, pp. 555–565, 2001.

R. D. Alvarez, M. N. Barnes, J. Gomez-Navarro et al., “A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial,” Clinical Cancer Research, vol. 6, no. 8, pp. 3081–3087, 2000.

R. W. Strube and S. Y. Chen, “Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-Fc intrabodies,” Journal of Immunological Methods, vol. 263, no. 1-2, pp. 149–167, 2002.

T. Gura, “Therapeutic antibodies: magic bullets hit the target,” Nature, vol. 417, pp. 584–586, 2002.

Y. Izumi, L. Xu, E. di Tomaso, et al., “Tumour biology: herceptin acts as an anti-angiogenic cocktail,” Nature, vol. 416, pp. 279–280, 2002.

P. M. Cardarelli, Q. Maire, B. Dana et al., “Binding to CD20 by anti-B1 antibody or F(ab')2 is sufficient for induction of apoptosis in B-cell lines,” Cancer Immunology, Immunotherapy, vol. 51, no. 1, pp. 15–24, 2002.

C. L. Vogel, M. A. Cobleigh, and D. Tripathy, “Efficacy and safety of Herceptin (trastuzumab) as a single agent in first-line treatment of HER2-overexpressing in Metastatic Breast Cancer (HER2+/MBC),” Breast Cancer Research and Treatment, vol. 50, p. 232, 1998.

S. Koido, Y. Tanaka, H. Tajiri, and J. Gong, “Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells,” Vaccine, vol. 25, no. 14, pp. 2610–2619, 2007.

P. S. Chowdhury and H. Wu, “Tailor-made antibody therapeutics,” Methods, vol. 36, no. 1, pp. 11–24, 2005.

R. E. Kontermann, M. G. Wing, and G. Winter, “Complement recruitment using bispecific diabodies,” Nature Biotechnology, vol. 15, no. 7, pp. 629–631, 1997.

P. A. Emanuel, J. Dang, J. S. Gebhardt et al., “Recombinant antibodies: a new reagent for biological agent detection,” Biosensors and Bioelectronics, vol. 14, no. 10-11, pp. 751–759, 2000.

J. Luka, P. M. Arlen, and A. Bristol, “Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5AC,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 934757, 8 pages, 2011.

H. R. Hoogenboom, A. D. Griffiths, K. S. Johnson, D. J. Chiswell, P. Hudson, and G. Winter, “Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains,” Nucleic Acids Research, vol. 19, no. 15, pp. 4133–4137, 1991.

R. A. Griep, C. van Twisk, R. J. Kerschbaumer et al., “pSKAP/S: an expression vector for the production of single-chain Fv alkaline phosphatase fusion proteins,” Protein Expression and Purification, vol. 16, no. 1, pp. 63–69, 1999.

R. A. Griep, M. Prins, C. van Twisk et al., “Application of phage display in selecting Tomato spotted wilt virus-specific single-chain antibodies (scFvs) for sensitive diagnosis in ELISA,” Phytopathology, vol. 90, no. 2, pp. 183–190, 2000.

J. Liu, D. Wei, F. Qian et al., “pPIC9-Fc: a vector system for the production of single-chain Fv-Fc fusions in Pichia pastoris as detection reagents in vitro,” Journal of Biochemistry, vol. 134, no. 6, pp. 911–917, 2003.

R. J. Kerschbaumer, S. Hirschl, A. Kaufmann, M. Ibl, R. Koenig, and G. Himmler, “Single-chain Fv fusion proteins suitable as coating and detecting reagents in a double antibody sandwich enzyme-linked Immunosorbent assay,” Analytical Biochemistry, vol. 249, no. 2, pp. 219–227, 1997.

K. Harper, R. L. Toth, M. A. Mayo, and L. Torrance, “Properties of a panel of single chain variable fragments against Potato leafroll virus obtained from two phage display libraries,” Journal of Virological Methods, vol. 81, no. 1-2, pp. 159–168, 1999.

R. A. Griep, C. Van Twisk, J. M. Van Der Wolf, and A. Schots, “Fluobodies: green fluorescent single-chain Fv fusion proteins,” Journal of Immunological Methods, vol. 230, no. 1-2, pp. 121–130, 1999.

K. Morino, H. Katsumi, Y. Akahori et al., “Antibody fusions with fluorescent proteins: a versatile reagent for profiling protein expression,” Journal of Immunological Methods, vol. 257, no. 1-2, pp. 175–184, 2001.

P. Oelschlaeger, S. Srikant-Iyer, S. Lange, J. Schmitt, and R. D. Schmid, “Fluorophor-linked immunosorbent assay: a time- and cost-saving method for the characterization of antibody fragments using a fusion protein of a single-chain antibody fragment and enhanced green fluorescent protein,” Analytical Biochemistry, vol. 309, no. 1, pp. 27–34, 2002.

R. E. Gross, “Breast cancer: risk factors, screening, and prevention,” Seminars in oncology nursing, vol. 16, no. 3, pp. 176–184, 2000.

R. T. Chlebowski, D. E. Collyar, M. R. Somerfield, and D. G. Pfister, “American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene,” Journal of Clinical Oncology, vol. 17, no. 6, pp. 1939–1955, 1999.

P. Carter, “Improving the efficacy of antibody-based cancer therapies,” Nature Reviews Cancer, vol. 1, no. 2, pp. 118–129, 2001.

A. Ghadersohi, K. Chitta, W. R. Greco et al., “Tumor antigens and markers for breast and ovarian cancers,” Front Biosci, vol. 7, pp. 48–57, 2002.

L. G. Presta, “Engineering antibodies for therapy,” Current Pharmaceutical Biotechnology, vol. 3, no. 3, pp. 237–256, 2002.

S. P. Treon, N. Raje, and K. C. Anderson, “Immunotherapeutic strategies for the treatment of plasma cell malignancies,” Seminars in Oncology, vol. 27, no. 5, pp. 598–613, 2000.

P. J. Yazaki, L. Shively, C. Clark et al., “Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications,” Journal of Immunological Methods, vol. 253, no. 1-2, pp. 195–208, 2001.

A. M. Ali, B. K. Ong, K. Yusoff, et al., “Generation of stable hybridoma clone secreting monoclonal antibody against breast cancer,” Journal of Molecular Microbiology and Biotechnology, vol. 4, no. 2, pp. 123–131, 1996.

A. F. A. Bakar, N. B. Alitheen, Y. S. Keong, M. Hamid, S. A. M. Ali, and A. M. Ali, “A mouse igM monoclonal antibody recognizes breast and colon cancer,” Hybridoma, vol. 28, no. 3, pp. 199–203, 2009.

N. Kida, T. Yoshimura, K. Mori, and K. Hayashi, “Hormonal regulation of synthesis and secretion of pS2 protein relevant to growth of human breast cancer cells (MCF-7),” Cancer Research, vol. 49, no. 13, pp. 3494–3498, 1989.

D. Yuan, F. J. Hendler, and E. S. Vitetta, “Characterization of a monoclonal antibody reactive with a subset of human breast tumors,” Journal of the National Cancer Institute, vol. 68, no. 5, pp. 719–728, 1982.

L. Plessers, E. Bosmans, A. Cox et al., “Production and immunohistochemical reactivity of mouse anti-epithelial monoclonal antibodies raised against human breast cancer cells,” Anticancer Research, vol. 10, no. 1, pp. 271–277, 1990.